November 13, 2024
Marinus Pharmaceuticals Slashes 45% of Workforce Following Disappointing Phase 3 Trial Results
Marinus Pharmaceuticals, staff layoffs, phase 3 trials, ganaxolone, refractory status epilepticus, RAISE trial, TrustTSC trial
BioNTech Invests $800M in PD-L1xVEGF-A Bispecific, Aiming to Challenge Keytruda Dominance
BioNTech, Keytruda, PD-L1xVEGF-A bispecific, Biotheus, cancer immunotherapy, pharmaceutical industry
23andMe Restructures, Cuts 40% of Workforce and Ends Therapeutics Division Amid Financial Struggles
23andMe, layoffs, therapeutics division, financial struggles, genetic testing, data security
UnitedHealth’s Optum Defends $3.3 Billion Acquisition of Amedisys Amid DOJ Lawsuit
Optum, Amedisys, UnitedHealth, DOJ, Acquisition, Healthcare, Antitrust
FDA Denies Full Approval for Ocaliva in Primary Biliary Cholangitis, Accelerated Approval Stands
FDA, Ocaliva, Intercept Pharmaceuticals, primary biliary cholangitis, accelerated approval, rare liver disease
Syndax’s Revumenib Shows Promising Results in Acute Leukemia Trials, Paving Way for FDA Approval
Revumenib, Acute Leukemia, AUGMENT-101, SAVE Trial, BEAT AML, Syndax Pharmaceuticals, FDA Approval
Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data
Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides
FDA Issues Second Clinical Hold on Kezar’s Zetomipzomib Program Within Two Months
Kezar Life Sciences, Zetomipzomib, FDA Clinical Hold, Lupus Nephritis, Autoimmune Hepatitis, Clinical Trials
Novartis and Schrödinger Forge $150M Drug Discovery Partnership with Billions in Potential Milestones
Novartis, Schrödinger, drug discovery pact, $150M upfront payment, multiyear collaboration, multi-target agreement.
Novartis Joins Eurovision 2025 as Official Partner
Eurovision 2025, Novartis, Official Partner, Basel, Switzerland